Next Article in Journal
Successful Allogeneic Bone Marrow Transplantation Using Immunosuppressive Conditioning Regimen for a Patient with Red Blood Cell Transfusion-Dependent Pyruvate Kinase Deficiency Anemia
Previous Article in Journal
Immunoistochemical Expression of PD-1 and PD-L1 in Bone Marrow Biopsies of Patients with Acute Myeloid Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 12
Issue 1
10.4081/hr.2020.8368
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression

by
Yusuke Yamashita
1,
Yoshikazu Hori
1,
Hideki Kosako
1,
Takehiro Oiwa
1,
Kenji Warigaya
2,
Toshiki Mushino
1,
Shogo Murata
1,
Masakazu Fujimoto
2,
Akinori Nishikawa
1,
Shin-ichi Murata
2,
Takashi Sonoki
1 and
Shinobu Tamura
1,*
1
Department of Hematology/Oncology, Wakayama Medical University, Wakayama 641-8509, Japan
2
Department of Diagnostic Pathology, Wakayama Medical University, Wakayama 641-8509, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2020, 12(1), 8368; https://doi.org/10.4081/hr.2020.8368
Submission received: 3 November 2019 / Revised: 30 December 2019 / Accepted: 7 January 2020 / Published: 15 May 2020

Abstract

Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”). A 54-year-old woman was diagnosed with ALK-ALCL in leukemic phase, characterized by an extremely poor prognosis. Lymphoma cells in this case showed chromosomal translocation 1p36.1- encoded RUNX3 and overexpression of its protein. She was refractory to CHOP and salvage chemotherapy. Fortunately, she achieved complete remission with three cycles of Brentuximab vedotin (BV) and underwent umbilical cord blood transplantation. However, she died due to treatment-related mortality on day 129. The autopsy findings showed no lymphoma cells. Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years. BV may be an effective option for ALK-ALCL in leukemic phase.
Keywords: ALK-negative anaplastic large cell lymphoma; Brentuximab vedotin; leukemic phase; RUNX3 ALK-negative anaplastic large cell lymphoma; Brentuximab vedotin; leukemic phase; RUNX3

Share and Cite

MDPI and ACS Style

Yamashita, Y.; Hori, Y.; Kosako, H.; Oiwa, T.; Warigaya, K.; Mushino, T.; Murata, S.; Fujimoto, M.; Nishikawa, A.; Murata, S.-i.; et al. Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression. Hematol. Rep. 2020, 12, 8368. https://doi.org/10.4081/hr.2020.8368

AMA Style

Yamashita Y, Hori Y, Kosako H, Oiwa T, Warigaya K, Mushino T, Murata S, Fujimoto M, Nishikawa A, Murata S-i, et al. Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression. Hematology Reports. 2020; 12(1):8368. https://doi.org/10.4081/hr.2020.8368

Chicago/Turabian Style

Yamashita, Yusuke, Yoshikazu Hori, Hideki Kosako, Takehiro Oiwa, Kenji Warigaya, Toshiki Mushino, Shogo Murata, Masakazu Fujimoto, Akinori Nishikawa, Shin-ichi Murata, and et al. 2020. "Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression" Hematology Reports 12, no. 1: 8368. https://doi.org/10.4081/hr.2020.8368

APA Style

Yamashita, Y., Hori, Y., Kosako, H., Oiwa, T., Warigaya, K., Mushino, T., Murata, S., Fujimoto, M., Nishikawa, A., Murata, S. -i., Sonoki, T., & Tamura, S. (2020). Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression. Hematology Reports, 12(1), 8368. https://doi.org/10.4081/hr.2020.8368

Article Metrics

Back to TopTop